The record
- Vertical
- Oncology
- Sub-segment
- Antibody technologies
- Product type
- Therapeutics
- Stage
- Seed
- Headquarters
- Portugal
- Region
- Europe
- Founded
- 2019
What they do
Founded in 2019 as a spin-off from NOVA University of Lisbon, CellmAbs was co-founded by CEO Nuno Prego Ramos and Prof. Paula Videira. Its work covered monoclonal antibodies targeting cancer-specific antigens, including antibody-drug conjugates, bispecific T-cell engagers and cell therapies. CellmAbs raised a single US$1.6 million seed investment in June 2019. Portugal Ventures and Bionova Capital are listed separately as supporters. On 9 January 2024, CellmAbs announced a patent assignment and licence agreement under which BioNTech acquired one preclinical antibody candidate and additional ADC technology. Terms included upfront and near-term payments, possible milestone payments and tiered royalties.
Investors
- Portugal Ventures
- Bionova Capital
Sources
Related companies